A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Clinical trial NCT04923893 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04923893
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-19
- Primary completion
- 2029-02-14
- Enrollment
- 743
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.